To include your compound in the COVID-19 Resource Center, submit it here.

Regulatory milestones

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.88 (10%) to $31.04 last week after FDA approved a BLA for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand. Auxilium has rights to the injectable form of collagenase from BioSpecifics Technologies Corp. (NASDAQ:BSTC), which was up $1.09 to $28.09.

Biota Holdings Ltd. (ASX:BTA) was up A$0.03 to A$2.03 last week after Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) submitted an NDA in Japan for laninamivir (CS-8958) to treat influenza. Daiichi has Japanese rights to the second-generation long-acting neuraminidase inhibitor (LANI).

InterMune Inc. (NASDAQ:ITMN) gained $0.09 to $15.70 last week on news that FDA's Pulmonary-Allergy Drug Advisory Committee will

Read the full 1105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers